Edgewise Therapeutics (EWTX) Accounts Payables (2020 - 2026)

Edgewise Therapeutics has reported Accounts Payables for 7 years, with the latest figure at $7.3 million in Q1 2026.

• Quarterly Accounts Payables fell 17.02% year-over-year to $7.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.3 million (down 17.02% YoY) and the FY2025 annual result came in at $6.0 million, up 7.65% from the prior year.
• Accounts Payables climbed to $7.3 million in Q1 2026 per EWTX's latest filing, from $6.0 million in the prior quarter.
• Over five years, Accounts Payables peaked at $8.8 million in Q1 2025 and troughed at $2.8 million in Q2 2022.
• A 5-year average of $5.7 million and a median of $5.6 million in 2024 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2022 and 2023: Accounts Payables soared 229.43% in 2022, then slumped 34.07% in 2023.
• Over 5 years, Accounts Payables stood at $6.1 million in 2022, then sank by 34.07% to $4.0 million in 2023, then soared by 38.61% to $5.6 million in 2024, then grew by 7.65% to $6.0 million in 2025, then rose by 21.43% to $7.3 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $7.3 million, $6.0 million, and $6.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.